Walleye Capital LLC Buys Shares of 267,743 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Walleye Capital LLC acquired a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 267,743 shares of the specialty pharmaceutical company's stock, valued at approximately $2,268,000. Walleye Capital LLC owned approximately 0.54% of KalVista Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp increased its holdings in KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company's stock valued at $14,725,000 after purchasing an additional 515,179 shares during the last quarter. Schroder Investment Management Group boosted its position in KalVista Pharmaceuticals by 86.8% during the fourth quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company's stock valued at $6,758,000 after purchasing an additional 374,213 shares during the last quarter. Vanguard Group Inc. boosted its position in KalVista Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company's stock valued at $19,102,000 after purchasing an additional 104,716 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in KalVista Pharmaceuticals during the fourth quarter valued at approximately $634,000. Finally, Barclays PLC boosted its position in KalVista Pharmaceuticals by 418.5% during the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company's stock valued at $778,000 after purchasing an additional 54,257 shares during the last quarter.

Insider Activity

In related news, insider Paul K. Audhya sold 3,125 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the sale, the insider now owns 100,334 shares of the company's stock, valued at $985,279.88. This represents a 3.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Venrock Healthcare Capital Par acquired 43,707 shares of the business's stock in a transaction that occurred on Thursday, January 30th. The shares were purchased at an average cost of $8.76 per share, with a total value of $382,873.32. Following the transaction, the insider now directly owns 4,986,480 shares of the company's stock, valued at $43,681,564.80. This trade represents a 0.88 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 261,055 shares of company stock valued at $2,397,646 and sold 17,292 shares valued at $184,625. 10.50% of the stock is currently owned by company insiders.

KalVista Pharmaceuticals Stock Up 2.2 %

Shares of KalVista Pharmaceuticals stock traded up $0.28 during trading on Thursday, reaching $12.73. The company's stock had a trading volume of 138,666 shares, compared to its average volume of 403,975. The business's 50-day moving average price is $11.49 and its 200-day moving average price is $10.34. The firm has a market cap of $632.88 million, a PE ratio of -3.50 and a beta of 0.39. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $15.50.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. JMP Securities began coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an "outperform" rating and a $19.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Jones Trading reiterated a "buy" rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Finally, TD Cowen initiated coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating and a $30.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $24.83.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).